GSK growth driven by R&D acceleration and long-acting HIV therapies
GSK says leadership is accelerating R&D, launching more phase III trials, and simplifying operations, with major savings reinvested into the pipeline. Long-acting HIV injectables, oncology assets and Shingrix are key drivers, with margin stability expected.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.